Targeting the FGFR Pathway in Patients with Advanced Solid Tumors

Clin Cancer Res. 2024 Oct 15;30(20):4549-4551. doi: 10.1158/1078-0432.CCR-24-1711.

Abstract

In the phase II FUZE trial targeting the FGFR pathway, Debio 1347 showed limited antitumor activity and manageable toxicity in patients with advanced solid tumors. Results from transcriptome-based analysis enhanced our understanding of the genomic landscape of FGFR fusion-driven tumors, informing clinical trial design and generating hypotheses for resistance mechanisms. See related article by Grivas et al., p. 4572.

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Molecular Targeted Therapy / methods
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Neoplasms* / pathology
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use
  • Quinoxalines
  • Receptors, Fibroblast Growth Factor* / antagonists & inhibitors
  • Receptors, Fibroblast Growth Factor* / genetics
  • Receptors, Fibroblast Growth Factor* / metabolism
  • Signal Transduction* / drug effects

Substances

  • Receptors, Fibroblast Growth Factor
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrazoles
  • erdafitinib
  • Quinoxalines